Checked
State dataHealth
Capmatinib
Published by State of Virginia · Updated 09/29/2026
- Last updated
- 09/29/2026
- First published 02/27/2026
- Update frequency
- Not listed
- Formats
- Web only
- Coverage
- Virginia
- Statewide
About this dataset
TABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coated tablets in 150 mg and 200 mg strengths and works by inhibiting certain proteins involved in cancer cell growth. This information was generated using AI and is provided for informational and research purposes only.
Files and access
Links open the official government source
- Capmatinibaccessdata.fda.govWeb page
Links open outside websites we do not control.
Frequently asked questions
- Who publishes Capmatinib?
- State of Virginia publishes this dataset on Virginia Open Data Portal.
- How often is it updated?
- The publisher does not list a schedule. The last update was on 09/29/2026.
- How do I download it?
- Use the official source link above to view or request the data.
Similar data from other publishers
- CapmatinibU.S. Department of Health & Human Services · U.S. Food and Drug AdministrationTABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coatedUpdated 03/17/2025Yearly
- CabozantinibU.S. Department of Health & Human Services · U.S. Food and Drug AdministrationCABOMETYX is a prescription medication containing cabozantinib, a kinase inhibitor that helps treat certain advanced cancers. It comes as oral tablets in strengths of 20 mg, 40 mg, and 60 mg, manufactured by Exelixis, Inc. This information was generated using Updated 03/17/2025Yearly
- FostamatinibU.S. Department of Health & Human Services · U.S. Food and Drug AdministrationTavalisse (fostamatinib) is an oral prescription drug manufactured by Rigel Pharmaceuticals, Inc., available as 100mg and 150mg tablets. It is used to treat low platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to Updated 03/17/2025Yearly
- CeritinibU.S. Department of Health & Human Services · U.S. Food and Drug AdministrationZykadia (ceritinib) is a prescription oral tablet made by Novartis Pharmaceuticals Corporation. It is a kinase inhibitor used to treat certain types of lung cancer, such as ALK-positive metastatic non-small cell lung cancer. Each tablet contains 150 mg of ceriUpdated 03/17/2025Yearly
Where this catalog comes from
- Data.gov CatalogU.S. General Services Administration
- State and local open data portalsSocrata Discovery API
- State and city CKAN portalsCalifornia, Virginia, Boston, Houston and more
- Government ArcGIS Hub sitesCity and county GIS data
Catalog checked 10/21/2026
We list dataset descriptions only. Downloads and APIs link straight to the official government source, which holds the current version and its terms of use.
Source: Virginia Open Data Portal · Last updated 10/21/2026 · Listing only; the data stays with the publisher
Share: